Other intangible aspects of the selection process were important as well. "Waters is good at listening to its customers, understanding their requirements, and adding features and making improvements that help us meet our scientific requirements," added Benkestock.
Benkestock's plans for the Synapt HDMS System are far-ranging including structure elucidation of metabolites and impurities, ligand screening during early drug discovery, protein and peptide work, protein identification and studying post-translation modifications, and target characterization.
Medivir gave its employees a better look at the Synapt HDMS System during an inauguration event on Thursday, October 25 at corporate headquarters.
Waters introduced the Synapt HDMS System at the American Society of Mass Spectrometry annual meeting in Seattle in June of 2006. It is the first commercially-available mass spectrometer with the ability to analyze ions by their size, shape and charge in addition to mass.
Other customers include Cambridge University, Oxford University, Utrecht University, University of Leeds, Max Planck Institute, and the University of Warwick.
For more information: http://www.waters.com/hdms.
About Medivir AB (http://www.medivir.com)
Medivir aims to develop protease inhibitors into innovative pharmaceuticals to be used against major widespread diseases and improve the quality of life for a number of patient groups. Medivir has several partnerships with pharmaceutical companies and has one investigational drug in phase III clinical trials, three in phase II and two in phase I. Other protease projects are in the late preclinical stage.
|SOURCE Waters Corporation|
Copyright©2007 PR Newswire.
All rights reserved